Navigation Links
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Date:12/28/2007

nd disorders of the central nervous system. For more information, visit http://www.novadel.com.

About Hana Biosciences

Hana Biosciences, Inc. is a South San Francisco, Calif.-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. Additional information on Hana Biosciences can be found at http://www.hanabiosciences.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Introducing Strativa Pharmaceuticals
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... 28, 2014 It’s a hard truth: Nearly ... to further their post-secondary education are failing to obtain a ... this year. And according to an analysis by The ... veteran students’ uninformed choice of college majors, which leads to ... the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... Calif. , July 28, 2014  InterMune, Inc. ... will release its second quarter 2014 financial results at ... 6, 2014. A live conference call and webcast will be ... same day. Interested investors and others may ... or +1 212-231-2900 (international), conference ID#21728775. A replay of the ...
(Date:7/28/2014)... Research and Markets has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to determine the size of a particle in a material ... the size of particles as it can affect the functionality ... determine the behavior and nature of a material, and for ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4InterMune to Release Second Quarter Financial Results on August 6 2Global Particle Size Analysis Market 2014-2018 2
... from McGill,s Physics Department and Mike Lilly from Sandia ... electronic circuits. It is formed by two wires separated ... This discovery, published in the journal Nature Nanotechnology ... and power of the ever smaller integrated circuits of ...
... LONDON, December 7, 2011 Silence Therapeutics plc ... ( RNAi ) therapeutics company, announces a positive outcome from the ... (EPO) over opposition to Silence,s granted European Patent EP 1 536 ... The granted patent refers to the gene target PKN3, protein ...
... 2011  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 2.875% Convertible Senior Notes due February 15, 2015 ... $1,000 principal amount or approximately $6.44 per share, effective December ... May 1, 2015 (May 2015 Notes) is 135.9849 shares of ...
Cached Biology Technology:Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 2Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 3Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 4PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes 2
(Date:7/27/2014)... study has revealed that nicotine and cotinine, a metabolite ... a certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ... leaves and ultimately ends up in the tobacco smoke. ... liver, where it is activated by a variety of ... has revealed that nicotine can partially interfere with the ...
(Date:7/27/2014)... the southern Western Ghats, a mountain range along the west ... that any mayfly belonging to the genus Labiobaetis ... called Labiobaetis soldani , "is named in honor of ... of the Ephemeroptera of Palaearctic and Oriental realms," according to ... in the Journal of Insect Science . , The ...
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2New drug target can break down cancer's barrier against treatment 2
... antibacterial medicine that kills the superbug MRSA is being ... Trust. The Seeding Drug Discovery initiative is aimed at ... unmet need. , Prolysis, an R&D company based ... Drug Discovery awards for its new antibacterial compounds aimed ...
... discovery in stem cell research may mean big things for ... a research team at the University of Kentucky published their ... , The researchers genetically mapped a stem cell gene and ... the investigation all the way through to the identification of ...
... as SORL1 may be a factor in the development of ... discovered. The genetic clue, which could lead to a better ... Genetics online, Jan. 14, 2007, and was supported in part ... researchers suggest that faulty versions of the SORL1 gene contribute ...
Cached Biology News:New antibacterials being developed to tackle MRSA superbug 2Researchers first to map gene that regulates adult stem cell growth 2Scientists find new genetic clue to cause of Alzheimer's disease 2
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
... Attoglow Western Blot Analysis Kit is ... kit developed by Biochain. It detects ... g) or yoctomole (10 -24 ... three parts: Millennium Enhancer, protein interaction ...
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
... the early 80s Biosearch Technologies has ... oligonucleotide tools to accelerate the discovery ... you need dual-labeled FRET probes and ... oligos for microarray applications, Biosearch can ...
Biology Products: